Livmoniplimab

Phase 3Monoclonal antibody

Livmoniplimab is one of 109 small molecule programs targeting Hepatocellular Carcinoma (HCC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular Carcinoma (HCC)Active, not recruiting

Locally Advanced or Metastatic Solid TumorsActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Hepatocellular CarcinomaRecruiting

Hepatocellular Carcinoma (HCC)Phase 1

Active, not recruiting

Locally Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Livmoniplimab

AbbVie

Phase 3

2 2

Viread

Gilead

Preclinical

1 3

Sovaldi

Gilead

Preclinical

1 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Coreg

Akero Therapeutics

Preclinical

2 6

Doptelet

AAkarx

Preclinical

1 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Vermox

WWim Janssens

Preclinical

1 9

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Valemetostat

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hepatocellular Carcinoma

NCT05822752

Q1 2027

Phase 1Active, not recruiting

Hepatocellular Carcinoma (HCC)

NCT06487559

Q2 2027

Phase 1Active, not recruiting

Locally Advanced or Metastatic Solid Tumors

NCT03821935

Q3 2028

Phase 2Active, not recruiting

Urothelial Carcinoma

NCT06632951

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT05822752·130 enrolled

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Recruiting· AbbVie logo

AbbVie·Phase 2/3·NCT06109272·660 enrolled

Urothelial Carcinoma1 trial

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06632951·150 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT03821935·364 enrolled

Non-Small Cell Lung Cancer1 trial

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06236438·840 enrolled

Hepatocellular Carcinoma (HCC)1 trial

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint Inhibitor

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT06487559·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Livmoniplimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Livmoniplimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Livmoniplimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Livmoniplimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2028

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Urothelial Carcinoma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News